Join to View Full Profile
Lincoln Tower 1140G1800 Cannon DriveColumbus, OH 43210
Phone+1 614-293-6989
Fax+1 614-293-7526
Dr. Saad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ayman Saad is a Hematology Specialist based in Columbus, OH, with a subspecialty in Hematologic Oncology. He completed his residency in Internal Medicine at the University of Maryland Medical Center Midtown Campus and his fellowship in Hematology and Medical Oncology at West Virginia University. Dr. Saad is experienced in conditions such as amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and hematopoietic stem cell transplantation. He has several publications in journals including Blood Advances and Cancer Medicine, some of which have been cited numerous times. Dr. Saad is involved in clinical trials, notably concerning Acute Lymphocytic Leukemia and Haploidentical Stem Cell Transplant.
Education & Training
West Virginia UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
University of Maryland Medical Center Midtown CampusResidency, Internal Medicine, 2002 - 2005
Ain Shams University Faculty of MedicineClass of 1994
Certifications & Licensure
CA State Medical License 2012 - 2026
OH State Medical License 2018 - 2024
AL State Medical License 2012 - 2018
WI State Medical License 2008 - 2013
WV State Medical License 2005 - 2009
MD State Medical License 2004 - 2005
American Board of Internal Medicine Hematology
Clinical Trials
- Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia Start of enrollment: 2013 Aug 27
- Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis Start of enrollment: 2013 Aug 27
- Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) Start of enrollment: 2014 Oct 09
- Join now to see all
Publications & Presentations
PubMed
- 21 citationsImpact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.Brittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, Noel Estrada-Merly, Lohith Gowda
Blood Advances. 2023-06-27 - 2 citationsOutcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents.Muhammad Salman Faisal, Walter Hanel, Timothy Voorhees, Rui Li, Ying Huang
Cancer Medicine. 2023-04-01 - 11 citationsNCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022.Ayman Saad, Alison Loren, Javier Bolaños-Meade, George Chen, Daniel Couriel
Journal of the National Comprehensive Cancer Network. 2023-02-01
Abstracts/Posters
- Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell TransplantationAyman Saad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgki...Ayman Saad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Impact of T-Cell Dose on Gvhd Risk after Allogeneic HLA-Matched PBSC Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 DataClinically Relevant Abs...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Professional Memberships
- Member
Other Languages
- Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
